Exact Mass: 415.1783
Exact Mass Matches: 415.1783
Found 180 metabolites which its exact mass value is equals to given mass value 415.1783
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Mavelertinib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163952 - EGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
Rupatadine
R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist Rupatadine is a second-generation tricyclic H1-antihistamine.
4,8-Methano-8aH-bisbenzofuro[3,2-e:2',3'-g]isoquinoline-1,8a-diol,7-(cyclopropylmethyl)-5,6,7,8,9,14b-hexahydro-, (4bS,8R,8aS,14bR)-
Sabeluzole
C26170 - Protective Agent > C1509 - Neuroprotective Agent
(S)-2-((S)-3-(1H-Imidazol-4-yl)-2-((S)-pyrrolidine-2-carboxamido)Propanamido)-3-(4-hydroxyphenyl)Propanoic acid
Ala Asp Asn Pro
Ala Asp Pro Asn
Ala Asn Asp Pro
Ala Asn Pro Asp
Ala Pro Asp Asn
Ala Pro Asn Asp
Asp Ala Asn Pro
Asp Ala Pro Asn
Asp Gly Pro Gln
Asp Gly Gln Pro
Asp Asn Ala Pro
Asp Asn Pro Ala
Asp Pro Ala Asn
Asp Pro Gly Gln
Asp Pro Asn Ala
Asp Pro Gln Gly
Asp Gln Gly Pro
Asp Gln Pro Gly
Glu Gly Asn Pro
Glu Gly Pro Asn
Glu Asn Gly Pro
Glu Asn Pro Gly
Glu Pro Gly Asn
Glu Pro Asn Gly
Gly Asp Pro Gln
Gly Asp Gln Pro
Gly Glu Asn Pro
Gly Glu Pro Asn
Gly Gly Pro Trp
Gly Gly Trp Pro
Gly Asn Glu Pro
Gly Asn Pro Glu
Gly Pro Asp Gln
Gly Pro Glu Asn
Gly Pro Gly Trp
Gly Pro Asn Glu
Gly Pro Gln Asp
Gly Pro Trp Gly
Gly Gln Asp Pro
Gly Gln Pro Asp
Gly Trp Gly Pro
Gly Trp Pro Gly
Asn Ala Asp Pro
Asn Ala Pro Asp
Asn Asp Ala Pro
Asn Asp Pro Ala
Asn Glu Gly Pro
Asn Glu Pro Gly
Asn Gly Glu Pro
Asn Gly Pro Glu
Asn Pro Ala Asp
Asn Pro Asp Ala
Asn Pro Glu Gly
Asn Pro Gly Glu
Pro Ala Asp Asn
Pro Ala Asn Asp
Pro Asp Ala Asn
Pro Asp Gly Gln
Pro Asp Asn Ala
Pro Asp Gln Gly
Pro Glu Gly Asn
Pro Glu Asn Gly
Pro Gly Asp Gln
Pro Gly Glu Asn
Pro Gly Gly Trp
Pro Gly Asn Glu
Pro Gly Gln Asp
Pro Gly Trp Gly
Pro Asn Ala Asp
Pro Asn Asp Ala
Pro Asn Glu Gly
Pro Asn Gly Glu
Pro Gln Asp Gly
Pro Gln Gly Asp
Pro Trp Gly Gly
Gln Asp Gly Pro
Gln Asp Pro Gly
Gln Gly Asp Pro
Gln Gly Pro Asp
Gln Pro Asp Gly
Gln Pro Gly Asp
Trp Gly Gly Pro
Trp Gly Pro Gly
Trp Pro Gly Gly
Benzeneethanol, 4-[1-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-1-methylethyl]-, 4-methylbenzenesulfonate (ester)
(S)-2-TERT-BUTOXYCARBONYLAMINO-3-[4-(DIETHOXY-PHOSPHORYLMETHYL)-PHENYL]-PROPIONIC ACID
(S)-3-(4-ACETYLPHENYL)-4-ISOPROPYLOXAZOLIDIN-2-ONE
Thiourea, N-[2-(5,6-dimethyl-1H-benzimidazol-2-yl)ethyl]-N-phenyl-N-(3-pyridinylmethyl)- (9CI)
3-ethynyl-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide
N-([1,1-Biphenyl]-4-ylmethyl)-6-phenyl-3-(pyridin-2-yl)-1,2,4-triazin-5-amine
ML228 (CID-46742353) is a potent the Hypoxia Inducible Factor (HIF) pathway activator with EC50 of 1 μM. ML228 potently activates HIF in vitro as well as its downstream target VEGF[1][2].
1-[1-(1-benzothiophen-2-yl)cyclohexyl]piperidine Maleate
5-[[4-(2-Amino-2-oxoethoxy)-3-methoxyphenyl]methylamino]-2-(4-morpholinyl)benzoic acid
4-[3-(4-methoxyphenyl)-1H-pyrazol-5-yl]-1-[[3-(trifluoromethyl)phenyl]methyl]piperidine
(2S)-1-[4-({6-[(2,6-Difluorophenyl)amino]pyrimidin-4-YL}amino)phenoxy]-3-(dimethylamino)propan-2-OL
(2R)-1-[4-({6-[(2,6-Difluorophenyl)amino]pyrimidin-4-YL}amino)phenoxy]-3-(dimethylamino)propan-2-OL
Rupatadine
R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist
4,8-Methano-8aH-bisbenzofuro[3,2-e:2',3'-g]isoquinoline-1,8a-diol,7-(cyclopropylmethyl)-5,6,7,8,9,14b-hexahydro-, (4bS,8R,8aS,14bR)-
Ala-Asn-Asp-Pro
A tetrapeptide composed of L-alanyl, L-asparagyl, L-aspartyl, and L-proline residues joined in sequence.
6-phenyl-N-[(3-phenylphenyl)methyl]-3-(2-pyridinyl)-1,2,4-triazin-5-amine
[2-(2,5-dimethylanilino)-2-oxoethyl] (E)-3-(2-methoxyphenyl)-2-phenylprop-2-enoate
BC1618
BC1618, an orally active Fbxo48 inhibitory compound, stimulates Ampk-dependent signaling (via preventing activated pAmpkα from Fbxo48-mediated degradation). BC1618 promotes mitochondrial fission, facilitates autophagy and improves hepatic insulin sensitivity[1].